Quick Answer
Summit Therapeutics Inc. reported Research And Development Expense of $59.47 million for the year ending 2023.
- Summit Therapeutics Inc. showed an increase of +14.4% in Research And Development Expense from 2022 to 2023.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2024.
- XBRL data for this metric is available from 2016 to 2023 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $9.95 million | Q1 2020: $12.91 million | Q2 2020: $13.57 million | Q3 2020: $13.73 million | Q1 2021: $18.38 million | Q2 2021: $23.92 million | Q3 2021: $19.94 million | Q1 2022: $20.56 million | Q2 2022: $9.01 million | Q3 2022: $17.05 million | Q1 2023: $9.88 million | Q2 2023: $9.45 million | Q3 2023: $15.32 million | Q1 2024: $30.87 million.
- Over the full 9 years of available data (2016 to 2023), Summit Therapeutics Inc.'s Research And Development Expense has grown by 252.8%.
- Historical annual values: Fiscal year 2023: $59.47 million | Fiscal year 2022: $52.00 million | Fiscal year 2021: $85.35 million | Fiscal year 2020: $53.27 million | Fiscal year 2019: $39.81 million | Fiscal year 2019: $52.00 million | Fiscal year 2018: $28.98 million | Fiscal year 2017: $18.95 million | Fiscal year 2016: $16.86 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: